Safer Medicines - putting patient safety first

Putting patient safety first

Image Slider

Latest News

Health professionals agree that new medicines should be tested using methods demonstrated to be the most predictive of safety for humans

Dods conducted an online survey of 2,512 UK health and care professionals in March 2016. 

They were asked one question about their perception of pharmaceutical testing regulations on behalf of Safer Medicines Trust.

The overwhelming majority of health professionals (79 per cent) agree that pharmaceutical companies should be legally obliged to test new medicines using methods demonstrated to be the most predictive of safety for humans.

Just three per cent of health professionals disagreed that pharmaceutical companies should be legally obliged to test new medicines using methods demonstrated to be the most predictive of safety for humans.

See full results here


Introducing our new Pharmaceutical Director

We are delighted to welcome Dr Gerry Kenna to Safer Medicines Trust, and look forward to him continuing to innovate and forge a route to improved safety of medicines, through human-relevant methods. 
 Dr Gerry Kenna is a Drug Safety Consultant and a leading figure in the field of human drug induced liver injury.  Following his initial scientific training in biochemistry, at the Universities of Leeds (BSc Hons) and London (PhD), Dr Kenna established and led academic research teams which, for 19 years, studied the mechanisms by which medicines and other chemicals may damage cells of the liver.   He then moved to industry (at Zeneca, Syngenta and AstraZeneca), where for 14 years he used his expertise to support human safety assessment of new medicines and agrochemicals.  During this time, he also led research teams which developed improved human safety testing methods.  These used human tissues and did not require use of animals.  Dr Kenna is committed to ensuring that such human-relevant approaches are used routinely, by scientists in industry and in regulatory agencies, to aid the invention and development of safe new medicines.

Newsletter 2016

Read our latest newsletter, with reflections on 10 years of progress


See more latest news here.

Share
Follow Us